Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;12:2887. doi: 10.1038/s41467-021-23240-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Top 20 downregulated metabolites in muscles treated with AAV6:Yap shRNA ranked by −log₁₀ p value, (b) Acylcarnitine levels in Soleus muscles examined 4 weeks after administration of AAV6:LacZ shRNA or AAV6:Yap shRNA vector (n = 6, mean ± SEM, * indicates p < 0.05 with exact p values provided in source data, two-sided t test without adjustment for multiple comparisons), (c) selected triglyceride species in Soleus muscles treated as in (b) (n = 6 biologically independent animals, mean ± SEM, * indicates p < 0.05 with exact p values provided in source data, two-sided t test without adjustment for multiple comparisions), (d) Total fatty acid oxidation (tracer present in cell and media acid-soluble metabolites and CO₂ gas phase) in pmol/h/mg tissue (n = 12 biologically independent animals, mean ± SEM, * shows significant difference, p = 0.03, two-sided t test), (e) Incomplete fatty acid oxidation (tracer in cell and media acid-soluble metabolites) and (f) complete fatty acid oxidation to CO₂ (tracer present in CO₂ gas phase only) in pmol/h/mg tissue in EDL muscles analysed 2 weeks after injection of AAV6:lacZ-shRNA or AAV6:Yap-shRNA vectors (n = 12 biologically independent animals, mean ± SEM, * shows significant difference, p = 0.03 and 0.71 respectively, two-sided t test), (g) Representative images of Dihydroethidium (red) and DAPI (blue) staining in Soleus muscles treated with AAV6:lacZ-shRNA and AAV6:Yap-shRNA and assessed 8 weeks after treatment (n = 10 biologically independent animals, scale bars indicate 50 μm).